Cargando…

Intravesical BCG in bladder cancer induces innate immune responses against SARS-CoV-2

BCG is the most efficient adjuvant therapy for high-risk, non-muscle-invasive bladder cancer (NMIBC). Both innate and adaptive immune responses have been implicated in BCG-mediated effects. BCG vaccination can boost innate immune responses via trained immunity (TI), resulting in an increased resista...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pichler, Renate, Diem, Gabriel, Hackl, Hubert, Koutník, Jiří, Mertens, Laura S., D`Andrea, David, Pradere, Benjamin, Soria, Francesco, Mari, Andrea, Laukhtina, Ekaterina, Krajewski, Wojciech, Teoh, Jeremy Yuen-Chun, Del Guidice, Francesco, Moschini, Marco, Thurnher, Martin, Posch, Wilfried
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374029/ https://www.ncbi.nlm.nih.gov/pubmed/37520557 http://dx.doi.org/10.3389/fimmu.2023.1202157

Ejemplares similares

Immune responses against SARS-CoV-2 wildtype in unvaccinated patients with high-risk NMIBC undergoing intravesical BCG therapy
por: Pichler, R., et al.
Publicado: (2023)

Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer
por: Pichler, Renate, et al.
Publicado: (2016)

Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis
por: Del Giudice, Francesco, et al.
Publicado: (2022)

Pott's disease post intravesical BCG
por: Jain, Anika
Publicado: (2023)

The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy
por: D'Andrea, David, et al.
Publicado: (2022)

Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis
por: Del Giudice, Francesco, et al.
Publicado: (2023)

Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017)

Expression of ADAM Proteases in Bladder Cancer Patients with BCG Failure: A Pilot Study
por: Pichler, Renate, et al.
Publicado: (2021)

The use of intravesical BCG in urothelial carcinoma of the bladder
por: Alhunaidi, Omar, et al.
Publicado: (2019)

Impact of sex on outcomes after surgery for non-muscle-invasive and muscle-invasive bladder urothelial carcinoma: a systematic review and meta-analysis
por: Mori, Keiichiro, et al.
Publicado: (2022)

Challenges to Improve the Stability and Efficacy of an Intravesical BCG Product
por: Hozouri, Hamidreza, et al.
Publicado: (2014)

Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
por: To, Uyen, et al.
Publicado: (2014)

Protective role of intravesical BCG in COVID-19 severity
por: Gallegos, Héctor, et al.
Publicado: (2021)

An uncommon cause of miliary disease: intravesical BCG immunotherapy
por: Azevedo, Marcelo, et al.
Publicado: (2021)

Assessing the Performance of 18F-FDG PET/CT in Bladder Cancer: A Narrative Review of Current Evidence
por: Bacchiani, Mara, et al.
Publicado: (2023)

Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer
por: Buffen, Kathrin, et al.
Publicado: (2014)

Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
por: Bhat, Suresh, et al.
Publicado: (2015)

Case Presentation: Lung Consolidation as Sequelae of BCG Sepsis After Combined Intravesical and Intraurethral BCG
por: Strich, Jeffrey R., et al.
Publicado: (2017)

Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal?
por: D’Andrea, David, et al.
Publicado: (2019)

BCGitis: A rare complication after intravesical BCG therapy
por: Oliveira, Maria João, et al.
Publicado: (2015)

Bladder Sparing Therapy for BCG Failures – I – Intravesical Immunotherapy
por: Messing, Edward M.
Publicado: (2017)

Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer
por: Seegobin, Karan, et al.
Publicado: (2017)

Reactive Arthritis – A Rare Complication of Intravesical BCG Instillation
por: Freixa, Marta, et al.
Publicado: (2020)

Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
por: Lukacs, S., et al.
Publicado: (2013)

Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes
por: Krajewski, Wojciech, et al.
Publicado: (2020)

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007)

Mycobacterial Osteomyelitis of the Spine Following Intravesical BCG Therapy for Bladder Cancer
por: Mackel, Charles E, et al.
Publicado: (2016)

Differential diagnosis of reactive arthritis in a patient with intravesical BCG immunotherapy
por: Aguridă, Aida Roxana, et al.
Publicado: (2014)

Tuberculous Orchitis Following Intravesical Bacille Calmette-Guérin (BCG) Therapy
por: Klebanov, Nikolai, et al.
Publicado: (2018)

Role of Intravesical BCG as a Therapeutic Vaccine for Treatment of Bladder Carcinoma
por: Doroud, Delaram, et al.
Publicado: (2022)

Systemic Bacillus Calmette-Guérin (BCG) Infection and Accompanying Warm Autoimmune Haemolytic Anaemia Following Intravesical BCG Immunotherapy
por: Güven, Alper Tuna, et al.
Publicado: (2023)

Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
por: Zhao, Hongda, et al.
Publicado: (2021)

The Impact of Diagnostic Ureteroscopy Prior to Radical Nephroureterectomy on Oncological Outcomes in Patients with Upper Tract Urothelial Carcinoma: A Comprehensive Systematic Review and Meta-Analysis
por: Nowak, Łukasz, et al.
Publicado: (2021)

Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG
Publicado: (2015)

Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report
por: Huang, Jeffrey, et al.
Publicado: (2017)

Acute Hepatitis Induced by Intravesical BCG Therapy: A Rare but Serious Complication
por: Abid, Hakima, et al.
Publicado: (2021)

Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer
por: Vilares, Ana T., et al.
Publicado: (2022)

Incidental discovery of a case of renal tuberculoma after intravesical BCG treatment
por: Sikpa, Komi Hola, et al.
Publicado: (2022)

Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure?
por: Anastay, Vassili, et al.
Publicado: (2023)

Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer
por: Pichler, Renate, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hul43580ht91fm0hbd38au486g